From bench to bedside: Integrating biomarkers of sarcopenia into frailty care pathways

Q. How can imaging and biochemical markers enhance the way we currently identify and assess sarcopenia within frailty care pathways?

In the clinical setting, Dual-energy X-ray Absorptiometry (DXA) and Bioelectrical Impedance Analysis (BIA) are probably the most “practice-ready” imaging tools for measuring muscle mass due to their availability and established cut-offs, while Point-of-Care Ultrasound is rapidly gaining utility for assessing muscle quality at the bedside. In fact, I am leading an ESCEO initiative to promote increased ultrasound use in MSK care.

Biochemically, the Sarcopenia Index (Creatinine/Cystatin C ratio) shows the greatest readiness for routine use as a simple, blood-based proxy for muscle mass. However, regulatory bodies like the FDA and EMA are prioritizing a different suite of “qualified biomarkers” for use in clinical trials to support drug development rather than frailty care improvement in a clinical context. These include N-terminal Type III Procollagen (P3NP), which has been formally identified by the FNIH Sarcopenia Project and ESCEO as a key marker of muscle protein synthesis, as well as the D3-Creatine dilution method for functional muscle mass, and systemic inflammatory markers such as IL-6 and TNF-α. However, cytokines like IL-6 and TNF-α are not specific for sarcopenia. While regulatory-prioritized markers are not yet in routine primary care, they are essential for bridging the “bench-to-bedside” gap and establishing the evidence needed for future clinical guidelines.

Key roles of biomarkers in improving sarcopenia detection and management:

• Biomarkers for early detection: These markers can identify at-risk individuals before functional decline and clinical symptoms become irreversible.
• Biomarkers for more objective assessment: They provide objective data that move beyond traditional diagnostic pathways which often rely heavily on physical performance.
• Biomarkers for risk stratification: Integrating these tools allows for better risk stratification, helping to identify which patients are most vulnerable to adverse outcomes.
• Biomarkers for monitoring disease progression: These tools offer better ways to monitor the progression of sarcopenia and the biological effectiveness of interventions over time.

Q. Which imaging and biochemical markers are showing the greatest clinical utility or readiness for routine practice?

For imaging markers, the current clinical utility is high for established techniques that measure muscle mass and quality, with emerging research focusing on their integration into routine care. In terms of biochemical markers, specific molecular markers are showing promise in clinical trials for their ability to provide insights into muscle health and systemic frailty. The International Conference on Frailty and Sarcopenia Research (ICFSR) provides clinical recommendations on which specific tools are most ready for implementation.

Q. What are the key challenges in integrating these biomarkers into existing frailty care pathways?

One major challenge with integrating biomarkers is bridging the bench-to-bedside gap, ensuring that laboratory science is effectively translated into practical, real-world clinical care. A further challenge lies in achieving operationalization, as healthcare systems often struggle to embed frailty research into structured, multidisciplinary services. Standardization also remains a key issue; unified definitions and diagnostic criteria, such as those being developed by the Global Leadership Initiative on Sarcopenia (GLIS), are needed to ensure consistency across different settings. Finally, resource constraints present an additional barrier, as implementing advanced imaging and biochemical testing requires substantial infrastructure and training for healthcare professionals.

Q. How might these markers influence clinical decision-making or personalize interventions for patients?

Objective data from markers allow for the development of more targeted and personalized intervention plans, such as specific dietary modifications or exercise programs, tailored to the individual’s biological profile. Markers can also help clinicians make informed interventions, for example deciding when to initiate early interventions, potentially preventing the shift from pre-frailty to severe frailty. In addition, by combining biomarker data with strengths-based assessments, clinicians can create more holistic care plans that address both biological deficits and a patient’s existing functional strengths.

Early detection depends on identifying which biomarkers offer the most clinical value for specific groups of “at-risk” patients. While scientists remain hopeful, I am not confident that we have yet reached the precision needed for routine risk stratification and optimal care planning. For broad adoption, clinicians need evidence-based guidelines, and healthcare systems require clear proof that these tools are a cost-effective investment for preventive care.

Q. What evidence and steps are needed to support inclusion of these biomarkers in clinical guidelines and broader adoption in frailty care?

Continued translational research evidence from clinical trials and cohort studies is needed to prove that biomarker-led identification improves long-term health outcomes and quality of life. Furthermore, achieving widespread adoption requires international consensus on the conceptual and operational definitions of sarcopenia, a key goal of the GLIS initiative. Equity in implementation must also be addressed, ensuring that these diagnostic tools are accessible across diverse populations, including indigenous communities, to promote health equity. Finally, integration into policy and treatment guidelines is crucial, with clear clinical guidance mandating the use of these markers in routine check-ups is essential for broad adoption in primary care.